Cytomx Thera (CTMX) Stock Price, Quote & News

Company Profile

CytomX Therapeutics, Inc. operates as an oncology-focused biopharmaceutical company that focuses on developing novel conditionally activated biologics localized to the tumor microenvironment. The company utilizes conditional activation platform technology for oncology biologics research and development comprising the validation of targets for antibody-drug conjugates (ADCs), opening therapeutic window for novel T-cell engagers (TCEs) targeting solid tumors, and increasing the therapeutic index f...

Industry: Biotechnology

Sector: Healthcare

Phone: 650 515 3185

Fax: 650 351 0353

Website: www.cytomx.com

Address:

151 Oyster Point Boulevard, Suite 400, South San Francisco, United States

Rick2058 Oct. 25 at 1:35 AM

$CTMX lackluster day may be overshadowed by post-market recovery.

0 · Reply

Turdsniffer Oct. 24 at 10:50 PM

$CTMX even for the day and week. Up for the month (bigly), up for the 3,6, and 12 month really bigly. The trend is your friend, friends. Have a great weekend

0 · Reply

1979to2012 Oct. 24 at 1:06 PM

$CTMX poised to continue uptrend

0 · Reply

SofaKing_Nuts Oct. 23 at 7:49 PM

$CTMX XL never sold a share, but is loading heavily right now

0 · Reply

buymoremakemore Oct. 23 at 3:47 PM

$CTMX my wife can get in at a discount.

0 · Reply

BigWangGang Oct. 23 at 3:34 PM

$RR $DVLT $RCAT $CTMX Yesterday was a great day to add

1 · Reply

buymoremakemore Oct. 22 at 8:01 PM

$CTMX Wow someone at close aggressively brought it down $0.10. Buying opportunity for people

0 · Reply

Gator5326 Oct. 22 at 7:45 PM

$CTMX Whole market was getting crushed. Nice recovery!

1 · Reply

biochirp Oct. 22 at 7:10 PM

$CTMX hope those who were waiting for a dip grabbed this one

0 · Reply

Turdsniffer Oct. 22 at 6:14 PM

$CTMX I hate averaging up but I added here

0 · Reply

CytomX Therapeutics Appoints Rachael Lester as Chief Business Officer

Oct 13, 2025, 11:45 PM EDT - 11 days ago

CytomX Therapeutics: Additional Run Up Into The Q1 2026 Readout Is Possible

Oct 12, 2025, 5:00 AM EDT - 13 days ago

Renewed Tariff Fears Spotlight Top Performing Stocks Since April

COMM NVDA PSIX SMH VSAT

Oct 6, 2025, 11:20 AM EDT - 18 days ago

CytomX: A Fresh Start With New Drugs After Total Pipeline Failure

Sep 10, 2025, 4:26 PM EDT - 6 weeks ago

CytomX Therapeutics, Inc. (CTMX) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript

Aug 28, 2025, 8:00 AM EDT - 2 months ago

CytomX Therapeutics to Present at Upcoming September Investor Conferences

Aug 13, 2025, 8:00 AM EDT - 2 months ago

CytomX Therapeutics Provides Update on CX-2051 Phase 1 Study

Aug 8, 2025, 6:10 PM EDT - 2 months ago

CytomX Therapeutics, Inc. (CTMX) Q2 2025 Earnings Call Transcript

Aug 8, 2025, 5:05 PM EDT - 2 months ago

CytomX Therapeutics: Updated Outlook For Late 2025

Aug 7, 2025, 4:10 PM EDT - 2 months ago

CytomX Therapeutics Announces Second Quarter 2025 Financial Results and Provides Business Update

Jul 31, 2025, 8:00 AM EDT - 3 months ago

CytomX Therapeutics to Report Second Quarter 2025 Financial Results on August 7, 2025

May 29, 2025, 8:00 AM EDT - 5 months ago

CytomX Therapeutics to Present at the Jefferies Global Healthcare Conference

May 19, 2025, 8:00 AM EDT - 5 months ago

CytomX Therapeutics Announces First Patient Dosed in Combination Arm of Phase 1 Study of CX-801 plus KEYTRUDA® (pembrolizumab) in Patients with Metastatic Melanoma

May 13, 2025, 10:34 AM EDT - 5 months ago

CytomX Therapeutics: Doubling Overnight On Phase 1 Data

May 12, 2025, 2:40 PM EDT - 5 months ago

CytomX Therapeutics, Inc. (CTMX) CX-2051 Phase 1 Interim Clinical Data Call (Transcript)

May 12, 2025, 11:11 AM EDT - 5 months ago

Nano-Cap CytomX Therapeutics Stock Surges On Heels Of Cancer Data Report

May 12, 2025, 6:50 AM EDT - 5 months ago

CytomX Therapeutics Announces Pricing of $100 Million Underwritten Offering of Common Stock

May 12, 2025, 6:15 AM EDT - 5 months ago

CytomX Announces Positive Interim Data From Phase 1 Dose Escalation Study of EpCAM Antibody Drug Conjugate (CX-2051) Candidate in Patients with Advanced Colorectal Cancer (CRC)

May 12, 2025, 6:15 AM EDT - 5 months ago

CytomX Therapeutics Announces First Quarter 2025 Financial Results and Provides Business Update

May 5, 2025, 8:00 AM EDT - 6 months ago

CytomX Therapeutics to Report First Quarter 2025 Financial Results on May 12, 2025

Apr 28, 2025, 4:00 PM EDT - 6 months ago

CytomX Therapeutics Presents Preclinical Data for mRNA Encoded Masked IL-12 Molecule in Collaboration with Moderna at AACR Annual Meeting

Mar 6, 2025, 6:34 PM EST - 8 months ago

CytomX Therapeutics, Inc. (CTMX) Q4 2024 Earnings Call Transcript

Mar 6, 2025, 4:10 PM EST - 8 months ago

CytomX Therapeutics Announces 2024 Financial Results and Provides Business Update

Mar 5, 2025, 8:00 AM EST - 8 months ago

CytomX Therapeutics to Present at the Barclays 27th Annual Global Healthcare Conference

Feb 27, 2025, 8:00 AM EST - 8 months ago

CytomX Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results on March 6, 2025

Jan 6, 2025, 4:05 PM EST - 10 months ago

CytomX Therapeutics Announces 2025 Strategic Pipeline Priorities and Provides Corporate Update

Nov 27, 2024, 8:00 AM EST - 11 months ago

CytomX Therapeutics to Present at the 36th Annual Piper Sandler Healthcare Conference

Nov 8, 2024, 8:44 AM EST - 1 year ago

CytomX Therapeutics, Inc. (CTMX) Q3 2024 Earnings Call Transcript

Nov 7, 2024, 4:10 PM EST - 1 year ago

CytomX Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update

Sep 9, 2024, 8:00 AM EDT - 1 year ago

CytomX Therapeutics Announces First Patient Dosed with CX-801, a Dually-Masked Interferon-Alpha 2b PROBODY®, in a Phase 1 Study in Patients with Solid Tumors

Aug 8, 2024, 4:10 PM EDT - 1 year ago

CytomX Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update

Jun 18, 2024, 8:00 AM EDT - 1 year ago

CytomX Therapeutics to Present at the H.C. Wainwright 2nd Annual Immune Cell Engager Virtual Conference

Jun 17, 2024, 4:15 PM EDT - 1 year ago

CytomX Therapeutics Promotes Chris Ogden to Chief Financial Officer

May 16, 2024, 4:15 PM EDT - 1 year ago

CytomX Therapeutics Announces New Employment Inducement Grants

May 9, 2024, 9:10 AM EDT - 1 year ago

CytomX stock down 30% despite encouraging cancer study results

May 8, 2024, 4:10 PM EDT - 1 year ago

CytomX Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update

May 8, 2024, 4:10 PM EDT - 1 year ago

CytomX Therapeutics Announces Positive Initial Phase 1a Dose Escalation Data for Monotherapy CX-904 (EGFRxCD3 PROBODY® T-Cell Engager)

May 7, 2024, 4:15 PM EDT - 1 year ago

CytomX Therapeutics Announces Clinical Collaboration with Merck to Evaluate CX-801 in Combination with KEYTRUDA® (pembrolizumab)

May 1, 2024, 8:00 AM EDT - 1 year ago

CytomX Therapeutics to Report First Quarter 2024 Results and Provide an Initial CX-904 Phase 1a Clinical Data Update on May 8, 2024

Apr 25, 2024, 6:33 PM EDT - 1 year ago

CytomX Therapeutics: I'm Bullish; There's More Than One Masked Immunotherapy Company In Town

Apr 8, 2024, 8:00 AM EDT - 1 year ago

CytomX Therapeutics Announces First Patient Dosed with CX-2051, a Conditionally Activated EpCAM-Directed ADC, in a Phase 1 Study in Patients with Advanced Solid Tumors

Apr 3, 2024, 8:00 AM EDT - 1 year ago

CytomX Therapeutics Announces Nomination of Second Clinical Candidate in Broad PROBODY® T-Cell Engaging Bispecific (TCB) Collaboration with Astellas

Mar 21, 2024, 8:00 AM EDT - 1 year ago

CytomX Therapeutics Appoints Dr. Zhen Su to Board of Directors

Mar 18, 2024, 8:00 AM EDT - 1 year ago

CytomX Therapeutics Announces Milestone Achievement in PROBODY® T-Cell Engaging Bispecific (TCB) Collaboration with Astellas

Mar 11, 2024, 6:39 PM EDT - 1 year ago

CytomX Therapeutics, Inc. (CTMX) Q4 2023 Earnings Call Transcript

Mar 11, 2024, 4:10 PM EDT - 1 year ago

CytomX Therapeutics Reports 2023 Financial Results and Provides Business Update

Mar 4, 2024, 8:00 AM EST - 1 year ago

CytomX Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results on March 11, 2024

Feb 27, 2024, 8:00 AM EST - 1 year ago

CytomX Therapeutics to Present at Upcoming March Investor Conferences

Jan 24, 2024, 8:00 AM EST - 1 year ago

CytomX Therapeutics Announces FDA Clearance of IND Applications for CX-2051, a Probody® Antibody Drug Conjugate (ADC) Targeting EpCAM and CX-801, a Conditionally Activated Interferon Alpha-2b

Jan 12, 2024, 8:00 AM EST - 1 year ago

CytomX Therapeutics to Present at the B. Riley Securities Virtual Annual Oncology Conference

Rick2058 Oct. 25 at 1:35 AM

$CTMX lackluster day may be overshadowed by post-market recovery.

0 · Reply

Turdsniffer Oct. 24 at 10:50 PM

$CTMX even for the day and week. Up for the month (bigly), up for the 3,6, and 12 month really bigly. The trend is your friend, friends. Have a great weekend

0 · Reply

1979to2012 Oct. 24 at 1:06 PM

$CTMX poised to continue uptrend

0 · Reply

SofaKing_Nuts Oct. 23 at 7:49 PM

$CTMX XL never sold a share, but is loading heavily right now

0 · Reply

buymoremakemore Oct. 23 at 3:47 PM

$CTMX my wife can get in at a discount.

0 · Reply

BigWangGang Oct. 23 at 3:34 PM

$RR $DVLT $RCAT $CTMX Yesterday was a great day to add

1 · Reply

buymoremakemore Oct. 22 at 8:01 PM

$CTMX Wow someone at close aggressively brought it down $0.10. Buying opportunity for people

0 · Reply

Gator5326 Oct. 22 at 7:45 PM

$CTMX Whole market was getting crushed. Nice recovery!

1 · Reply

biochirp Oct. 22 at 7:10 PM

$CTMX hope those who were waiting for a dip grabbed this one

0 · Reply

Turdsniffer Oct. 22 at 6:14 PM

$CTMX I hate averaging up but I added here

0 · Reply

Aldobe115 Oct. 22 at 5:27 PM

$CTMX

0 · Reply

winners18 Oct. 22 at 3:50 PM

$CTMX another adc deals https://www.msn.com/en-us/news/other/china-s-innovent-strikes-cancer-drug-deal-with-takeda-for-up-to-11-4-billion/ar-AA1OWobo?ocid=BingNewsVerp

0 · Reply

Biotech_Beast Oct. 21 at 9:34 PM

$EXEL I've had a look at the road ahead for EXEL and the STELLAR-303 data. Of course there could be competition from $AGEN and $CTMX and others, but EXEL does have a result in hand with STELLAR-303. https://seekingalpha.com/article/4831510-exelixis-digesting-big-stellar-303-update-and-road-ahead

1 · Reply

buymoremakemore Oct. 21 at 7:13 PM

$CTMX Buyout by 2027.

0 · Reply

sbale Oct. 21 at 5:29 PM

$CTMX Hitting new highs, multi year resistance is $9 and there is no wall until then. One spike is all it takes like $NERV.

0 · Reply

BiotechValues Oct. 21 at 2:07 PM

$BCAB $36M market cap vs. $CTMX $600M or 17x higher market cap. I know where I am placing my bet. Yesterday's EpCAM data was absolutely better than expected at low doses :)

1 · Reply

MapDaTrades Oct. 21 at 1:34 PM

$CTMX is my redemption for $SESN turned $CARM

0 · Reply

anachartanalyst Oct. 21 at 1:01 PM

$CTMX https://anachart.com/wp-content/uploads/ana_temp/1761051701_soc-img.jpg

0 · Reply

S_Franconi Oct. 21 at 12:56 PM

$CTMX At Deloitte Consulting, she held a leading role in the Life Sciences Strategy & Operations practice, as a thought leader and advisor to biotech clients on growth strategy, M&A, and new product planning and commercialization. Ms. Lester received a B.A. in neuroscience from University of Pennsylvania and an M.B.A. from the Kellogg School of Management at Northwestern University. https://replicatebioscience.com/members/rachael-lester-mba/

0 · Reply

biochirp Oct. 21 at 12:48 PM

$CTMX this really going to 5$+ soon

0 · Reply

S_Franconi Oct. 21 at 12:43 PM

$CTMX Ms. Lester served as Global Head of Strategic Asset Management at Onyx Pharmaceuticals, where she was responsible for portfolio management, strategic finance, sell-side corporate development, and innovation initiatives through the approvals of Kyprolis and Stivarga and acquisition by Amgen. https://replicatebioscience.com/members/rachael-lester-mba/

0 · Reply

S_Franconi Oct. 21 at 12:38 PM

$CTMX

0 · Reply

Market Cap	544.21M
Revenue (ttm)	138.10M
Net Income (ttm)	31.87M
EPS (ttm)	N/A
PE Ratio	6.05
Forward PE	63.56
Profit Margin	23.08%
Debt to Equity Ratio	0.00

Volume	1,738,800
Avg Vol	3,689,020
Day's Range	N/A - N/A
Shares Out	164.91M
Stochastic %K	12%
Beta	2.27
Analysts	Strong Sell
Price Target	$6.14